1705 related articles for article (PubMed ID: 845989)
1. Immunochemotherapy of malignant melanoma with chlorambucil-bound antimelanoma globulins: preliminary results in patients with disseminated disease.
Ghose T; Norvell ST; Guclu A; Bodurtha A; Tai J; MacDonald AS
J Natl Cancer Inst; 1977 Apr; 58(4):845-52. PubMed ID: 845989
[TBL] [Abstract][Full Text] [Related]
2. Immunochemotherapy of human malignant melanoma with chlorambucil-carrying antibody.
Ghose T; Norvell ST; Guclu A; Macdonald AS
Eur J Cancer (1965); 1975 May; 11(5):321-6. PubMed ID: 1171762
[No Abstract] [Full Text] [Related]
3. Results of administering B.C.G. to patients with melanoma.
Grant RM; Mackie R; Cochran AJ; Murray EL; Hoyle D; Ross C
Lancet; 1974 Nov; 2(7889):1096-100. PubMed ID: 4139404
[No Abstract] [Full Text] [Related]
4. [Results in the use of immunochemotherapy in patients with cutaneous malignant melanoma].
Calbo L; Gorgone S; Palmeri R; Salibra M; Melita P
Chir Ital; 1983 Aug; 35(4):519-25. PubMed ID: 6680859
[TBL] [Abstract][Full Text] [Related]
5. Topical dinitrochlorobenzene combined with systemic dacarbazine in the treatment of recurrent melanoma.
Strobbe LJ; Hart AA; Rümke P; Israels SP; Nieweg OE; Kroon BB
Melanoma Res; 1997 Dec; 7(6):507-12. PubMed ID: 9464624
[TBL] [Abstract][Full Text] [Related]
6. Immunochemotherapy of cancer with chlorambucil-carrying antibody.
Ghose T; Norvell ST; Guclu A; Cameron D; Bodurtha A; MacDonald AS
Br Med J; 1972 Aug; 3(5825):495-9. PubMed ID: 4560726
[TBL] [Abstract][Full Text] [Related]
7. [Immunochemotherapy of malignant melanoma. Epifocal administration of dinitrochlorobenzene (DNCB) combined with systemic chemotherapy with dacarbazine (DTIC)].
Trcka J; Kämpgen E; Becker JC; Schwaaf A; Bröcker EB
Hautarzt; 1998 Jan; 49(1):17-22. PubMed ID: 9522188
[TBL] [Abstract][Full Text] [Related]
8. Pilot studies using melanoma tumor-associated antigens (TAA) in specific-active immunochemotherapy of malignant melanoma.
Hollinshead A; Arlen M; Yonemoto R; Cohen M; Tanner K; Kundin WD; Scherrer J
Cancer; 1982 Apr; 49(7):1387-404. PubMed ID: 7059953
[TBL] [Abstract][Full Text] [Related]
9. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
Kirchner HH; Atzpodien J; Poliwoda H
Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
[TBL] [Abstract][Full Text] [Related]
10. Randomized trial of adjuvant therapy for "high risk" primary malignant melanoma.
Wood WC; Cosimi AB; Carey RW; Kaufman SD
Surgery; 1978 Jun; 83(6):677-81. PubMed ID: 644461
[TBL] [Abstract][Full Text] [Related]
11. [Diffuse melanosis with generalized and ocular metastasis in malignant melanoma].
Ring J; Emslander C
Hautarzt; 1984 Jun; 35(6):308-12. PubMed ID: 6469636
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy.
Wimmer I; Meyer JC; Seifert B; Dummer R; Flace A; Burg G
Cancer Res; 1997 Nov; 57(22):5073-6. PubMed ID: 9371505
[TBL] [Abstract][Full Text] [Related]
13. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
Avril MF; Aamdal S; Grob JJ; Hauschild A; Mohr P; Bonerandi JJ; Weichenthal M; Neuber K; Bieber T; Gilde K; Guillem Porta V; Fra J; Bonneterre J; Saïag P; Kamanabrou D; Pehamberger H; Sufliarsky J; Gonzalez Larriba JL; Scherrer A; Menu Y
J Clin Oncol; 2004 Mar; 22(6):1118-25. PubMed ID: 15020614
[TBL] [Abstract][Full Text] [Related]
14. DTIC vs. IFN-alpha plus DTIC in the treatment of patients with metastatic malignant melanoma.
Rudolf Z; Strojan P
Neoplasma; 1996; 43(2):93-7. PubMed ID: 8843969
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
[TBL] [Abstract][Full Text] [Related]
16. Cohort study of metastatic melanoma patients in the Dermatology Institute of Florence 1990/1997.
Moretti S; Carli P; Biggeri A; Volpi V; Pimpinelli N
J Eur Acad Dermatol Venereol; 2001 Jan; 15(1):30-3. PubMed ID: 11451318
[TBL] [Abstract][Full Text] [Related]
17. Treatment of melanoma by passive humoral immunotherapy using antibody drug synergism.
Everall KD; Dowd P; Davies DA; O'Neill GJ; Rowland GF
Lancet; 1977 May; 1(8021):1105-6. PubMed ID: 68204
[No Abstract] [Full Text] [Related]
18. Chemoimmunotherapy (DTIC and Corynebacterium parvum) as adjuvant treatment in malignant melanoma.
Karakousis CP; Didolkar MS; Lopez R; Baffi R; Moore R; Holyoke ED
Cancer Treat Rep; 1979; 63(11-12):1739-43. PubMed ID: 393377
[TBL] [Abstract][Full Text] [Related]
19. Active-specific immunotherapy for melanoma.
Mitchell MS; Harel W; Kempf RA; Hu E; Kan-Mitchell J; Boswell WD; Dean G; Stevenson L
J Clin Oncol; 1990 May; 8(5):856-69. PubMed ID: 2139701
[TBL] [Abstract][Full Text] [Related]
20. Active specific and active non-specific immunotherapy in patients with malignant melanoma.
Kokoschka EM; Cerni C; Micksche M
Oncology; 1977; 34(5):229-33. PubMed ID: 917456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
